Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1999 June;43(2) > The Quarterly Journal of Nuclear Medicine 1999 June;43(2):119-24

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 1999 June;43(2):119-24

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Polypeptides from phage display. A superior source of in vivo imaging agents

Ladner R. C.

From the Dyax Corp., Therapeutic and Diagnostic Division Cambridge, Massachusetts, USA


PDF


To ­decide wheth­er expe­ri­ence teach­es ­that ­small pro­teins and con­strained pep­tides hav­ing ­high affin­ity for molec­u­lar tar­gets can be engi­neered to ­have suit­able phar­ma­cok­i­net­ics for imag­ing. Phage dis­play, a molec­u­lar diver­sity tech­nol­o­gy, ­allows selec­tion of poly­pep­tides hav­ing ­high affin­ity and spec­i­fic­ity for ­almost any tar­get. These poly­pep­tides can be mod­i­fied in ­ways ­that ­improve phar­ma­cok­i­net­ics ­with accept­able ­impact on bind­ing. Often, rel­a­tive­ly few chang­es con­fers phar­ma­cok­i­net­ics suit­able for imag­ing on poly­pep­tides select­ed for affin­ity and spec­i­fic­ity to a tar­get and for stabil­ity. It is like­ly ­that few var­i­ants of ­phage-select­ed pro­teins and con­strained pep­tides ­will ­need to be test­ed to ­obtain a use­ful imag­ing ­agent.

inizio pagina